|
US7407955B2
(en)
|
2002-08-21 |
2008-08-05 |
Boehringer Ingelheim Pharma Gmbh & Co., Kg |
8-[3-amino-piperidin-1-yl]-xanthines, the preparation thereof and their use as pharmaceutical compositions
|
|
EP1599468B1
(en)
|
2003-01-14 |
2007-10-03 |
Arena Pharmaceuticals, Inc. |
1,2,3-trisubstituted aryl and heteroaryl derivatives as modulators of metabolism and the prophylaxis and treatment of disorders related thereto such as diabetes and hyperglycemia
|
|
AR045047A1
(es)
|
2003-07-11 |
2005-10-12 |
Arena Pharm Inc |
Derivados arilo y heteroarilo trisustituidos como moduladores del metabolismo y de la profilaxis y tratamiento de desordenes relacionados con los mismos
|
|
AR045697A1
(es)
|
2003-07-14 |
2005-11-09 |
Arena Pharm Inc |
Aril y heteroaril derivados fusionados como moduladores del metabolismo y la prevencion y tratamiento de trastornos relacionados con el mismo
|
|
US7501426B2
(en)
|
2004-02-18 |
2009-03-10 |
Boehringer Ingelheim International Gmbh |
8-[3-amino-piperidin-1-yl]-xanthines, their preparation and their use as pharmaceutical compositions
|
|
US7858800B2
(en)
*
|
2004-06-30 |
2010-12-28 |
Banyu Pharmaceutical Co., Ltd. |
Biaryl derivatives
|
|
DE102004054054A1
(de)
|
2004-11-05 |
2006-05-11 |
Boehringer Ingelheim Pharma Gmbh & Co. Kg |
Verfahren zur Herstellung chiraler 8-(3-Amino-piperidin-1-yl)-xanthine
|
|
GB0428212D0
(en)
*
|
2004-12-24 |
2005-01-26 |
Prosidion Ltd |
Compounds
|
|
JP5065908B2
(ja)
|
2004-12-24 |
2012-11-07 |
プロシディオン・リミテッド |
Gタンパク質結合受容体作動薬
|
|
MX2007007553A
(es)
*
|
2004-12-24 |
2007-08-15 |
Prosidion Ltd |
Agonistas del receptor acoplado a proteina g (gpr116) y uso de los mismos para tratar obesidad y diabetes.
|
|
GB0428514D0
(en)
*
|
2004-12-31 |
2005-02-09 |
Prosidion Ltd |
Compounds
|
|
DOP2006000008A
(es)
*
|
2005-01-10 |
2006-08-31 |
Arena Pharm Inc |
Terapia combinada para el tratamiento de la diabetes y afecciones relacionadas y para el tratamiento de afecciones que mejoran mediante un incremento de la concentración sanguínea de glp-1
|
|
WO2007003960A1
(en)
*
|
2005-06-30 |
2007-01-11 |
Prosidion Limited |
Gpcr agonists
|
|
US20090221644A1
(en)
*
|
2005-06-30 |
2009-09-03 |
Stuart Edward Bradley |
Gpcr Agonists
|
|
EP1910290A2
(en)
|
2005-06-30 |
2008-04-16 |
Prosidion Limited |
Gpcr agonists
|
|
DE102005035891A1
(de)
|
2005-07-30 |
2007-02-08 |
Boehringer Ingelheim Pharma Gmbh & Co. Kg |
8-(3-Amino-piperidin-1-yl)-xanthine, deren Herstellung und deren Verwendung als Arzneimittel
|
|
US20100261758A1
(en)
*
|
2006-03-28 |
2010-10-14 |
Novartis Ag |
Heterocyclic amides for use as pharmaceuticals
|
|
BRPI0710839A2
(pt)
*
|
2006-04-06 |
2011-08-23 |
Prosidion Ltd |
agonistas heterocìclicos de gpcr
|
|
GB0607196D0
(en)
*
|
2006-04-11 |
2006-05-17 |
Prosidion Ltd |
G-protein coupled receptor agonists
|
|
PE20071221A1
(es)
|
2006-04-11 |
2007-12-14 |
Arena Pharm Inc |
Agonistas del receptor gpr119 en metodos para aumentar la masa osea y para tratar la osteoporosis y otras afecciones caracterizadas por masa osea baja, y la terapia combinada relacionada a estos agonistas
|
|
CA2618488C
(en)
|
2006-04-11 |
2010-07-13 |
Arena Pharmaceuticals, Inc. |
Methods of using gpr119 receptor to identify compounds useful for increasing bone mass in an individual
|
|
SG174054A1
(en)
|
2006-05-04 |
2011-09-29 |
Boehringer Ingelheim Int |
Polymorphs
|
|
PE20110235A1
(es)
|
2006-05-04 |
2011-04-14 |
Boehringer Ingelheim Int |
Combinaciones farmaceuticas que comprenden linagliptina y metmorfina
|
|
EP1852108A1
(en)
|
2006-05-04 |
2007-11-07 |
Boehringer Ingelheim Pharma GmbH & Co.KG |
DPP IV inhibitor formulations
|
|
GB0610746D0
(en)
*
|
2006-06-01 |
2006-07-12 |
Prosidion Ltd |
Method of treatment
|
|
FR2903405B1
(fr)
|
2006-07-04 |
2011-09-09 |
Pasteur Institut |
Composes a effet potentialisateur de l'activite de l'ethionamide et leurs applications
|
|
AU2007283113A1
(en)
|
2006-08-08 |
2008-02-14 |
Sanofi-Aventis |
Arylaminoaryl-alkyl-substituted imidazolidine-2,4-diones, processes for preparing them, medicaments comprising these compounds, and their use
|
|
JP2010513272A
(ja)
|
2006-12-14 |
2010-04-30 |
メルク エンド カムパニー インコーポレーテッド |
アシルビピペリジニル化合物、そのような化合物を含む組成物、及び治療方法
|
|
US20100029688A1
(en)
|
2006-12-20 |
2010-02-04 |
Wood Harold B |
Bipiperidinyl compounds, compositions containing such compounds and methods of treatment
|
|
CL2007003841A1
(es)
*
|
2006-12-28 |
2008-03-14 |
Metabolex Inc |
Compuestos derivados de 4(5h-1 lambda-tiazol-2-il)piperidina; composicion farmaceutica que contiene a dichos compuestos; y su uso para tratar diabetes.
|
|
BRPI0806312A2
(pt)
*
|
2007-01-04 |
2011-09-06 |
Prosidion Ltd |
agonistas cgpr piperidina
|
|
PE20081659A1
(es)
|
2007-01-04 |
2008-10-24 |
Prosidion Ltd |
Agonistas de gpcr
|
|
GB0700122D0
(en)
|
2007-01-04 |
2007-02-14 |
Prosidion Ltd |
GPCR agonists
|
|
PE20081849A1
(es)
|
2007-01-04 |
2009-01-26 |
Prosidion Ltd |
Derivados de piperidin-4-il-propoxi-benzamida como agonistas de gpcr
|
|
EA015129B1
(ru)
|
2007-01-04 |
2011-06-30 |
Прозидион Лимитед |
Пиперидиновые агонисты gpcr
|
|
AU2008222812B2
(en)
*
|
2007-03-08 |
2012-03-22 |
Irm Llc |
Compounds and compositions as modulators of GPR119 activity
|
|
CN101754962B
(zh)
|
2007-07-19 |
2013-12-25 |
赛马拜制药公司 |
作为rup3或gpr119受体的激动剂治疗糖尿病和代谢性病症的n-氮杂环状经取代吡咯、吡唑、咪唑、三唑和四唑衍生物
|
|
EP2025674A1
(de)
|
2007-08-15 |
2009-02-18 |
sanofi-aventis |
Substituierte Tetrahydronaphthaline, Verfahren zu ihrer Herstellung und ihre Verwendung als Arzneimittel
|
|
US20100286112A1
(en)
|
2007-09-10 |
2010-11-11 |
Oscar Barba |
Compounds for the treatment of metabolic disorders
|
|
CA2697551C
(en)
|
2007-09-20 |
2013-03-12 |
Irm Llc |
Piperidine derivatives as modulators of gpr119 activity
|
|
GB0720389D0
(en)
|
2007-10-18 |
2008-11-12 |
Prosidion Ltd |
G-Protein Coupled Receptor Agonists
|
|
GB0720390D0
(en)
|
2007-10-18 |
2007-11-28 |
Prosidion Ltd |
G-Protein coupled receptor agonists
|
|
PE20140960A1
(es)
|
2008-04-03 |
2014-08-15 |
Boehringer Ingelheim Int |
Formulaciones que comprenden un inhibidor de dpp4
|
|
EP2146210A1
(en)
|
2008-04-07 |
2010-01-20 |
Arena Pharmaceuticals, Inc. |
Methods of using A G protein-coupled receptor to identify peptide YY (PYY) secretagogues and compounds useful in the treatment of conditions modulated by PYY
|
|
UY31968A
(es)
|
2008-07-09 |
2010-01-29 |
Sanofi Aventis |
Nuevos derivados heterocíclicos, sus procesos para su preparación, y sus usos terapéuticos
|
|
BRPI0916997A2
(pt)
|
2008-08-06 |
2020-12-15 |
Boehringer Ingelheim International Gmbh |
Inibidor de dpp-4 e seu uso
|
|
UY32030A
(es)
|
2008-08-06 |
2010-03-26 |
Boehringer Ingelheim Int |
"tratamiento para diabetes en pacientes inapropiados para terapia con metformina"
|
|
RU2011113823A
(ru)
|
2008-09-10 |
2012-10-20 |
БЕРИНГЕР ИНГЕЛЬХАЙМ ИНТЕРНАЦИОНАЛЬ ГмбХ (DE) |
Комбинированная терапия, предназначенная для лечения диабета и связанных с ним состояний
|
|
SG2014014013A
(en)
|
2008-09-22 |
2014-07-30 |
Cayman Chemical Co Inc |
Multiheteroaryl compounds as inhibitors of h-pgds and their use for treating prostaglandin d2 mediated diseases
|
|
US20200155558A1
(en)
|
2018-11-20 |
2020-05-21 |
Boehringer Ingelheim International Gmbh |
Treatment for diabetes in patients with insufficient glycemic control despite therapy with an oral antidiabetic drug
|
|
WO2010056907A2
(en)
*
|
2008-11-12 |
2010-05-20 |
The Scripps Research Institute |
Compounds that induce pancreatic beta-cell expansion
|
|
WO2010068601A1
(en)
|
2008-12-08 |
2010-06-17 |
Sanofi-Aventis |
A crystalline heteroaromatic fluoroglycoside hydrate, processes for making, methods of use and pharmaceutical compositions thereof
|
|
EP2382216A1
(en)
|
2008-12-23 |
2011-11-02 |
Boehringer Ingelheim International GmbH |
Salt forms of organic compound
|
|
EP2379542B1
(en)
|
2008-12-24 |
2013-02-13 |
Cadila Healthcare Limited |
Novel oxime derivatives
|
|
AR074990A1
(es)
|
2009-01-07 |
2011-03-02 |
Boehringer Ingelheim Int |
Tratamiento de diabetes en pacientes con un control glucemico inadecuado a pesar de la terapia con metformina
|
|
GB0904285D0
(en)
|
2009-03-12 |
2009-04-22 |
Prosidion Ltd |
Compounds for the treatment of metabolic disorders
|
|
GB0904284D0
(en)
|
2009-03-12 |
2009-04-22 |
Prosidion Ltd |
Compounds for the treatment of metabolic disorders
|
|
WO2010149685A1
(en)
|
2009-06-24 |
2010-12-29 |
Boehringer Ingelheim International Gmbh |
New compounds, pharmaceutical composition and methods relating thereto
|
|
AU2010264720A1
(en)
|
2009-06-24 |
2011-12-08 |
Boehringer Ingelheim International Gmbh |
New compounds, pharmaceutical composition and methods relating thereto
|
|
US8754112B2
(en)
|
2009-08-05 |
2014-06-17 |
Daiichi Sankyo Company, Limited |
Sulfone derivative
|
|
BR112012003973A2
(pt)
|
2009-08-26 |
2015-09-08 |
Sanofi Sa |
hidratos de fluoroglicosídeo heteroaromático cristalinos, produtos farmacêuticos compreendendo estes compostos e seu uso
|
|
EP3646859A1
(en)
|
2009-11-27 |
2020-05-06 |
Boehringer Ingelheim International GmbH |
Treatment of genotyped diabetic patients with dpp-iv inhibitors such as linagliptin
|
|
WO2011107494A1
(de)
|
2010-03-03 |
2011-09-09 |
Sanofi |
Neue aromatische glykosidderivate, diese verbindungen enthaltende arzneimittel und deren verwendung
|
|
US20130109703A1
(en)
|
2010-03-18 |
2013-05-02 |
Boehringer Ingelheim International Gmbh |
Combination of a GPR119 Agonist and the DPP-IV Inhibitor Linagliptin for Use in the Treatment of Diabetes and Related Conditions
|
|
GB201006166D0
(en)
|
2010-04-14 |
2010-05-26 |
Prosidion Ltd |
Compounds for the treatment of metabolic disorders
|
|
GB201006167D0
(en)
|
2010-04-14 |
2010-05-26 |
Prosidion Ltd |
Compounds for the treatment of metabolic disorders
|
|
NZ602921A
(en)
|
2010-05-05 |
2016-01-29 |
Boehringer Ingelheim Int |
Combination therapy comprising the administration of a glp-1 receptor agonist and a ddp-4 inhibitor
|
|
MX2012013465A
(es)
|
2010-05-17 |
2013-12-02 |
Array Biopharma Inc |
Lactamas sustituidas con piperidinilo como moduladores de gpr119.
|
|
TW201209054A
(en)
|
2010-05-28 |
2012-03-01 |
Prosidion Ltd |
Novel compounds
|
|
US8933024B2
(en)
|
2010-06-18 |
2015-01-13 |
Sanofi |
Azolopyridin-3-one derivatives as inhibitors of lipases and phospholipases
|
|
US8530413B2
(en)
|
2010-06-21 |
2013-09-10 |
Sanofi |
Heterocyclically substituted methoxyphenyl derivatives with an oxo group, processes for preparation thereof and use thereof as medicaments
|
|
ES2676209T3
(es)
|
2010-06-23 |
2018-07-17 |
Metabolex Inc. |
Composiciones de 5-etil-2-{4-[4-(4-tetrazol-1-il-fenoximetil)-tiazol-2-il]-piperidin-1-il}-pirimidina
|
|
KR20230051307A
(ko)
|
2010-06-24 |
2023-04-17 |
베링거 인겔하임 인터내셔날 게엠베하 |
당뇨병 요법
|
|
TW201215388A
(en)
|
2010-07-05 |
2012-04-16 |
Sanofi Sa |
(2-aryloxyacetylamino)phenylpropionic acid derivatives, processes for preparation thereof and use thereof as medicaments
|
|
TW201215387A
(en)
|
2010-07-05 |
2012-04-16 |
Sanofi Aventis |
Spirocyclically substituted 1,3-propane dioxide derivatives, processes for preparation thereof and use thereof as a medicament
|
|
TW201221505A
(en)
|
2010-07-05 |
2012-06-01 |
Sanofi Sa |
Aryloxyalkylene-substituted hydroxyphenylhexynoic acids, process for preparation thereof and use thereof as a medicament
|
|
AU2011305525B2
(en)
|
2010-09-22 |
2016-08-18 |
Arena Pharmaceuticals, Inc. |
Modulators of the GPR119 receptor and the treatment of disorders related thereto
|
|
WO2012046249A1
(en)
|
2010-10-08 |
2012-04-12 |
Cadila Healthcare Limited |
Novel gpr 119 agonists
|
|
BR112013009043B8
(pt)
|
2010-10-14 |
2019-09-17 |
Daiichi Sankyo Co Ltd |
composto, composição farmacêutica, e, uso de um composto
|
|
AR083878A1
(es)
|
2010-11-15 |
2013-03-27 |
Boehringer Ingelheim Int |
Terapia antidiabetica vasoprotectora y cardioprotectora, linagliptina, metodo de tratamiento
|
|
GB201114389D0
(en)
|
2011-08-22 |
2011-10-05 |
Prosidion Ltd |
Novel compounds
|
|
WO2012066077A1
(en)
|
2010-11-18 |
2012-05-24 |
Prosidion Limited |
1,4 di substituted pyrrolidine - 3 - yl -amine derivatives and their use for the treatment of metabolic disorders
|
|
US8710050B2
(en)
|
2011-03-08 |
2014-04-29 |
Sanofi |
Di and tri- substituted oxathiazine derivatives, method for the production, method for the production thereof, use thereof as medicine and drug containing said derivatives and use thereof
|
|
US8809325B2
(en)
|
2011-03-08 |
2014-08-19 |
Sanofi |
Benzyl-oxathiazine derivatives substituted with adamantane and noradamantane, medicaments containing said compounds and use thereof
|
|
WO2012120052A1
(de)
|
2011-03-08 |
2012-09-13 |
Sanofi |
Mit carbozyklen oder heterozyklen substituierte oxathiazinderivate, verfahren zu deren herstellung, diese verbindungen enthaltende arzneimittel und deren verwendung
|
|
US8895547B2
(en)
|
2011-03-08 |
2014-11-25 |
Sanofi |
Substituted phenyl-oxathiazine derivatives, method for producing them, drugs containing said compounds and the use thereof
|
|
WO2012120050A1
(de)
|
2011-03-08 |
2012-09-13 |
Sanofi |
Neue substituierte phenyl-oxathiazinderivate, verfahren zu deren herstellung, diese verbindungen enthaltende arzneimittel und deren verwendung
|
|
WO2012120056A1
(de)
|
2011-03-08 |
2012-09-13 |
Sanofi |
Tetrasubstituierte oxathiazinderivate, verfahren zu deren herstellung, ihre verwendung als medikament sowie sie enthaltendes arzneimittel und deren verwendung
|
|
WO2012120053A1
(de)
|
2011-03-08 |
2012-09-13 |
Sanofi |
Verzweigte oxathiazinderivate, verfahren zu deren herstellung, ihre verwendung als medikament sowie sie enthaltendes arzneimittel und deren verwendung
|
|
EP2683705B1
(de)
|
2011-03-08 |
2015-04-22 |
Sanofi |
Di- und trisubstituierte oxathiazinderivate, verfahren zu deren herstellung, ihre verwendung als medikament sowie sie enthaltendes arzneimittel und deren verwendung
|
|
EP2683701B1
(de)
|
2011-03-08 |
2014-12-24 |
Sanofi |
Mit benzyl- oder heteromethylengruppen substituierte oxathiazinderivate, verfahren zu deren herstellung, ihre verwendung als medikament sowie sie enthaltendes arzneimittel und deren verwendung
|
|
ES2602813T3
(es)
|
2011-06-09 |
2017-02-22 |
Rhizen Pharmaceuticals S.A. |
Nuevos compuestos como moduladores de GPR-119
|
|
AU2012285904C1
(en)
|
2011-07-15 |
2017-08-31 |
Boehringer Ingelheim International Gmbh |
Substituted quinazolines, the preparation thereof and the use thereof in pharmaceutical compositions
|
|
MX2014000929A
(es)
|
2011-07-29 |
2014-05-12 |
Daiichi Sankyo Co Ltd |
Derivados de amida sustituidos con n-hetero-anillo.
|
|
WO2013037390A1
(en)
|
2011-09-12 |
2013-03-21 |
Sanofi |
6-(4-hydroxy-phenyl)-3-styryl-1h-pyrazolo[3,4-b]pyridine-4-carboxylic acid amide derivatives as kinase inhibitors
|
|
EP2567959B1
(en)
|
2011-09-12 |
2014-04-16 |
Sanofi |
6-(4-hydroxy-phenyl)-3-styryl-1h-pyrazolo[3,4-b]pyridine-4-carboxylic acid amide derivatives as kinase inhibitors
|
|
WO2013045413A1
(en)
|
2011-09-27 |
2013-04-04 |
Sanofi |
6-(4-hydroxy-phenyl)-3-alkyl-1h-pyrazolo[3,4-b]pyridine-4-carboxylic acid amide derivatives as kinase inhibitors
|
|
AU2013210394A1
(en)
|
2012-01-18 |
2014-08-14 |
Daiichi Sankyo Company,Limited |
Substituted phenylazole derivative
|
|
US9555001B2
(en)
|
2012-03-07 |
2017-01-31 |
Boehringer Ingelheim International Gmbh |
Pharmaceutical composition and uses thereof
|
|
EP4151218A1
(en)
|
2012-05-14 |
2023-03-22 |
Boehringer Ingelheim International GmbH |
Linagliptin, a xanthine derivative as dpp-4 inhibitor, for use in the treatment of sirs and/or sepsis
|
|
US20130303462A1
(en)
|
2012-05-14 |
2013-11-14 |
Boehringer Ingelheim International Gmbh |
Use of a dpp-4 inhibitor in podocytes related disorders and/or nephrotic syndrome
|
|
WO2013174767A1
(en)
|
2012-05-24 |
2013-11-28 |
Boehringer Ingelheim International Gmbh |
A xanthine derivative as dpp -4 inhibitor for use in modifying food intake and regulating food preference
|
|
WO2014016191A1
(en)
*
|
2012-07-24 |
2014-01-30 |
Boehringer Ingelheim International Gmbh |
N-cyclopropyl-n-piperidinyl-amide derivatives and their use as gpr119 modulators
|
|
EP3110449B1
(en)
|
2014-02-28 |
2023-06-28 |
Boehringer Ingelheim International GmbH |
Medical use of a dpp-4 inhibitor
|
|
US10118890B2
(en)
|
2014-10-10 |
2018-11-06 |
The Research Foundation For The State University Of New York |
Trifluoromethoxylation of arenes via intramolecular trifluoromethoxy group migration
|
|
CN116850181A
(zh)
|
2015-01-06 |
2023-10-10 |
艾尼纳制药公司 |
治疗与s1p1受体有关的病症的方法
|
|
AU2016284162A1
(en)
|
2015-06-22 |
2018-02-01 |
Arena Pharmaceuticals, Inc. |
Crystalline L-arginine salt of (R)-2-(7-(4-cyclopentyl-3-(trifluoromethyl)benzyloxy)-1,2,3,4-tetrahydrocyclo-penta[b]indol-3-yl)acetic acid(Compound1) for use in SIP1 receptor-associated disorders
|
|
EP3468562A1
(en)
|
2016-06-10 |
2019-04-17 |
Boehringer Ingelheim International GmbH |
Combinations of linagliptin and metformin
|
|
CN117777121A
(zh)
|
2016-10-24 |
2024-03-29 |
詹森药业有限公司 |
化合物及其用途
|
|
EA201991650A1
(ru)
|
2017-01-06 |
2020-01-20 |
Юманити Терапьютикс, Инк. |
Способы лечения неврологических расстройств
|
|
AU2018220521A1
(en)
|
2017-02-16 |
2019-09-05 |
Arena Pharmaceuticals, Inc. |
Compounds and methods for treatment of primary biliary cholangitis
|
|
WO2019084157A1
(en)
*
|
2017-10-24 |
2019-05-02 |
Yumanity Therapeutics, Inc. |
COMPOUNDS AND USES THEREOF
|
|
AU2019238326B2
(en)
|
2018-03-23 |
2025-03-06 |
Janssen Pharmaceutica Nv |
Compounds and uses thereof
|
|
CN112566636A
(zh)
|
2018-04-25 |
2021-03-26 |
优曼尼蒂治疗公司 |
化合物及其用途
|
|
WO2019236757A1
(en)
|
2018-06-06 |
2019-12-12 |
Arena Pharmaceuticals, Inc. |
Methods of treating conditions related to the s1p1 receptor
|
|
JP7742775B2
(ja)
|
2019-01-24 |
2025-09-22 |
ヤンセン ファーマシューティカ エヌ.ベー. |
化合物及びその使用
|
|
EA202192047A1
(ru)
|
2019-11-13 |
2021-12-08 |
Юманити Терапьютикс, Инк. |
Соединения и их применение
|
|
WO2023122152A1
(en)
*
|
2021-12-22 |
2023-06-29 |
Praxis Precision Medicines, Inc. |
Kcnt1 inhibitors and methods of use
|
|
WO2025037036A1
(en)
*
|
2023-08-17 |
2025-02-20 |
Sanofi |
Pyridyl imidazoles, their preparation and their therapeutic application
|